Skip to content

Study · In vitro (cells) · 2021

4 results

Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability.

Teng H, Li C, Zhang Y, Lu M, Chopp M, Zhang ZG, Melcher-Mourgas M, Fleckenstein B

Neuroreport1 Mar 2021Cited by 32 (Europe PMC)

PMID33661804 (opens in a new tab)DOI10.1097/wnr.0000000000001598 (opens in a new tab)PepBankPUB-33661804
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In human cerebral endothelial cells, Cerebrolysin reduced and reversed tPA- and fibrin-impaired permeability.

    In plain wordsIn cells, Cerebrolysin reduced impaired permeability compared with tPA and fibrin exposure.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseEndothelial cell permeability
    Study

    humann: not reported in source

    Human cerebral endothelial cells
    Comparator
    tPA and fibrin exposure
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, Cerebrolysin significantly diminished and reversed tPA- and fibrin-impaired endothelial cell permeability,
  2. 02LabIn vitro (cells)Mechanism

    In human cerebral endothelial cells, Cerebrolysin reduced tPA- and fibrin-augmented proinflammatory and procoagulation proteins.

    In plain wordsIn cells, Cerebrolysin reduced inflammatory and coagulation proteins compared with tPA and fibrin exposure.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseProinflammatory and procoagulation proteins
    Study

    humann: not reported in source

    Human cerebral endothelial cells
    Comparator
    tPA and fibrin exposure
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    which was associated with significant reductions of tPA- and fibrin-augmented proinflammatory and procoagulation proteins and
  3. 03LabIn vitro (cells)Mechanism

    In human cerebral endothelial cells, Cerebrolysin elevated tPA- and fibrin-decreased tight junction proteins.

    In plain wordsIn cells, Cerebrolysin increased tight junction proteins compared with tPA and fibrin exposure.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseTight junction proteins
    Study

    humann: not reported in source

    Human cerebral endothelial cells
    Comparator
    tPA and fibrin exposure
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    significant elevations of tPA- and fibrin-decreased tight junction proteins.
  4. 04LabIn vitro (cells)Mechanism

    In human cerebral endothelial cells, Cerebrolysin reduced impaired permeability, whereas cerebroprotein hydrolysate did not show this reduction.

    In plain wordsIn cells, Cerebrolysin reduced impaired permeability, whereas cerebroprotein hydrolysate did not.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseEndothelial permeability compared with cerebroprotein hydrolysate
    Study

    humann: not reported in source

    Human cerebral endothelial cells
    Comparator
    Cerebroprotein hydrolysate
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The beneficial effect of Cerebrolysin appears specific because cerebroprotein hydrolysate, with a distinct peptide composition, failed to show the reduction of tPA- and fibrin-impaired permeability.
    1 context sentence
    Summary · context
    However, Cerebrolysin significantly diminished and reversed tPA- and fibrin-impaired endothelial cell permeability,

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT06078215

CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke

Poznan University of Medical Sciencesn = 35010 Jan 2023 to est. 31 Mar 2025

Acute Ischemic Stroke

Trial pageClinicalTrials.govUpdated 13 Oct 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.